Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:47:21 2024-03-28 pm EDT 5-day change 1st Jan Change
3.165 USD +2.76% Intraday chart for Poseida Therapeutics, Inc. +4.28% -5.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer MT
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024 CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M MT
Poseida Therapeutics, Inc. Announces Executive Changes CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Biotechnology Index CI
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating MT
Poseida Therapeutics Reports Positive Results of Phase 1 Blood Cancer Treatment Trial MT
Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment DJ
HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating MT
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology Annual Meeting CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Posts Q3 Revenue $9.4M MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Poseida Therapeutics, Inc. Announces Board Changes CI
Poseida Therapeutics, Inc. Announces Chief Executive Officer Changes CI
Poseida Therapeutics Names Kristin Yarema as CEO, Mark Gergen as Executive Chairman MT
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q2 Revenue $20M MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Poseida Therapeutics Secures $50 Million Strategic Investment From Astellas; Shares Gain MT
Poseida Therapeutics Shares Leap on Astellas Investments DJ
Poseida Therapeutics in $50 Million Investment Deal With Astellas DJ
Poseida Therapeutics, Inc. announced that it has received $24.999999 million in funding from Astellas US, LLC CI
Poseida Therapeutics, Inc. announced that it expects to receive $24.999999 million in funding from Astellas US, LLC CI
Poseida Therapeutics Says US FDA Clears Investigational New Drug Application for B-cell Malignancies Treatment Candidate MT
Chart Poseida Therapeutics, Inc.
More charts
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's approach to cell and gene therapies is based on its genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. Its P-MUC1C-ALLO1 is an allogeneic CAR-T product candidate with the potential to treat a range of solid tumor indications, including breast and other epithelial-derived cancers. Its product candidate, P-PSMA- ALLO1, is being developed for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. Its P-CD19CD20-ALLO1 is an allogeneic, CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.08 USD
Average target price
14 USD
Spread / Average Target
+354.55%
Consensus
  1. Stock
  2. Equities
  3. Stock Poseida Therapeutics, Inc. - Nasdaq
  4. News Poseida Therapeutics, Inc.
  5. Cantor Fitzgerald Starts Poseida Therapeutics at Overweight with $24 Price Target